Ask Warren

D&D Pharmatech

347850 · KOSDAQ · ₩347850 · 디앤디파마텍

₩40,800▲ ₩150 (0.37%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −15.66%
Market cap
₩1.9T
Enterprise value
₩1.8T
P/E
—
P/B
13.9×
Dividend yield
0.0%
ROE
−16.0%
Net margin
−785.5%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−65.0% from the high

₩34,500Today: ₩40,050 – ₩42,300₩116,600

Returns

  • 1W+0.5%
  • 1M−8.3%
  • 3M−26.5%
  • 6M−48.2%
  • YTD−55.6%
  • 1Y−15.7%
Volume today
339,707
0.6× the 20-day average
Traded today
₩14B
Listed shares
45,996,189
EPS (12 months)
−₩470
Earnings yield −1.2%
SellBuy
AI research · InitiationD&D Pharmatech: Share Price Down 79.9% in a Year as Losses Continue on Small RevenueThe filed numbers show a loss-making biotech with falling revenue, negative cash flow and a sharply lower share price.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

37Quiet
  • BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
  • MomentumFlat-4.7% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 27: buy ₩632M at the close (2.7% of 20-day average trading value)

Sep 28Last 20 trading days (% of average trading value)Oct 27

On its 31 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 4.9% of trading value and pointed the same way 29 of 31 times.

  • 2× KODEX KOSDAQ150 Leverage ₩515M
  • 2× TIGER KOSDAQ150 Leverage ₩61M
  • -1× KODEX KOSDAQ150 Futures Inverse ₩36M
  • 2× RISE KOSDAQ150 Futures Leverage ₩11M
  • 2× KIWOOM KOSDAQ150 Futures Leverage ₩2.7M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 40,600

Basis −0.49% · implied rate −11.2%

Open interest 3,883 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

D&D Pharmatech stock overview

D&D Pharmatech (디앤디파마텍, KRX: 347850) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biotech focused on discovering and developing innovative drugs based on GLP-1 peptide technology, targeting metabolic diseases such as obesity and MASH (metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative diseases like Parkinson's and Alzheimer's. Its shares closed at ₩40,800 on Oct 27, 2026, up 0.37% on the day, giving it a market value of ₩1.9T.

Key facts

Market cap
₩1.9T
Sector
Biotech & Pharma
Latest price change
+0.37%
As of
Oct 27, 2026
Main business
The company is a Korean biotech focused on discovering and developing innovative drugs based on GLP-1 peptide technology, targeting metabolic diseases such as obesity and MASH (metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative diseases like Parkinson's and Alzheimer's.

Quick answers about D&D Pharmatech

What does D&D Pharmatech do?
The company is a Korean biotech focused on discovering and developing innovative drugs based on GLP-1 peptide technology, targeting metabolic diseases such as obesity and MASH (metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative diseases like Parkinson's and Alzheimer's. Its main pipeline includes the oral obesity candidates partnered with Pfizer and the MASH candidate DD01, and it generates revenue mainly by licensing early-stage drug candidates to global pharmaceutical partners, with its clinical trials conducted mainly in the United States and North America.
What is the market cap of D&D Pharmatech?
The market capitalisation of D&D Pharmatech was ₩1.9T at the close on Oct 27, 2026.
Who are the largest shareholders of D&D Pharmatech?
According to the latest official filings, the largest reported holders are Lee Seul-gi (25.49%, as of Jun 11, 2026); Libright Holdings (4.84%, as of May 15, 2025); Interbest (4.52%, as of Feb 20, 2025).
When is the next earnings report from D&D Pharmatech?
Korean companies rarely announce results dates in advance. Based on when D&D Pharmatech filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own D&D Pharmatech?
Yes. The National Pension Service held 1.75% of D&D Pharmatech shares as of Dec 31, 2025.

Company profile

The company is a Korean biotech focused on discovering and developing innovative drugs based on GLP-1 peptide technology, targeting metabolic diseases such as obesity and MASH (metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative diseases like Parkinson's and Alzheimer's. Its main pipeline includes the oral obesity candidates partnered with Pfizer and the MASH candidate DD01, and it generates revenue mainly by licensing early-stage drug candidates to global pharmaceutical partners, with its clinical trials conducted mainly in the United States and North America.

Written by AI from the company's latest annual report.

Korean name
디앤디파마텍
Sector
Biotech & Pharma
Themes
Biotech (new drugs)Obesity drugsPharmaceuticals
CEO
이슬기
Founded
Nov 2014
Listed
May 2024
Listed shares
45,996,189
Fiscal year ends
Month 12
Website
www.ddpharmatech.com

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: D&D Pharmatech / 디앤디파마텍 / 347850 / KRX:347850

Source: KRX statistical information